Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01 août 2018 16h29 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 6
01 août 2018 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Announces Positive Top-line Results from Second Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
12 juil. 2018 07h00 HE
|
Zogenix, Inc.
Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008 versus Placebo for Adjunctive Treatment of Seizures ZX008 Also Demonstrated Statistical Significance in...
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
02 juil. 2018 16h32 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Welcomes New Global Chief Commercial Officer
02 juil. 2018 08h00 HE
|
Zogenix, Inc.
Ashish Sagrolikar Brings Over 25 Years of Global Pharmaceutical Sales, Marketing and Operations Experience to Zogenix EMERYVILLE, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc....
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01 juin 2018 16h24 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference
14 mai 2018 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Provides Corporate Update and Reports First Quarter Financial Results
09 mai 2018 16h01 HE
|
Zogenix, Inc.
Following receipt of Breakthrough Therapy Designation, conducted successful Type B meeting with FDA confirming adequacy of Phase 3 program for ZX008 NDA in Dravet syndromeStudy 1504 fully enrolled...
Zogenix to Release First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9
04 mai 2018 08h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
01 mai 2018 17h00 HE
|
Zogenix, Inc.
EMERYVILLE, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...